Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

Additional information

According to Regulation (EC) No 1907/2006, Annex X, article 8.9.1., column 2, testing of carcinogenicity is not indicated, as several studies investigating the genetic toxicity of sarcosines and sarcosinates in-vitro have shown that the substances of this category are not genotoxic. Moreover, the chronic and subchronic repeated dose toxicity tests via the oral route conducted with Sodium N-lauroylsarcosinate (CAS 137-16-6) revealed no substance-related adverse effects indicative for carcinogenicity such as hyperplasia or pre-neoplastic changes (e. g. metaplasia).


Justification for selection of carcinogenicity via oral route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.

Justification for selection of carcinogenicity via inhalation route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.

Justification for selection of carcinogenicity via dermal route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.